-
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
12 Apr 2024 18:27 GMT
… Double-Blind, Placebo-Controlled Trial
Poster Presentation
P009
April … was funded by UCB Pharma.
**STACCATO® alprazolam is … harmful for people with phenylketonuria. Neither non-clinical … aseptic meningitis develop, diagnostic workup and treatment should be …
-
Identification of Lower Grade Glioma Antigens Based on Ferroptosis Status for mRNA Vaccine Development
11 Apr 2024 12:01 GMT
… , this treatment still encounters a significant risk of developing acquired resistance … of mRNA vaccines in treating LGG needs to be … Prognosis. Technol Cancer Res Treat. 2021;20:15330338211011961. doi … Cerrato G, et al. Trial watch: peptide-based vaccines in …
-
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
04 Apr 2024 15:20 GMT
… U.S. Food and Drug Administration (FDA) for ECUR-506 in … are to assess the pharmacokinetics and efficacy of ECUR- … approach to treat OTC deficiency. “We hope that treatment with this … based on successful technology development and commercialization of the …
-
Phenylketonuria Market Report 2032: Epidemiology, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight
02 Apr 2024 10:22 GMT
… to grab major Phenylketonuria market share @ Phenylketonuria Treatment Landscape
Phenylketonuria Market Outlook
Phenylketonuria (PKU) is a …
-
PTC Therapeutics seeks European marketing approval for sepiapterin for Treatment of phenylketonuria
30 Mar 2024 10:39 GMT
… the treatment of paediatric and adult patients with phenylketonuria (PKU), … the phase 3 APHENITY trial in which sepiapterin … to treat the broad range of PKU patients.
Phenylketonuria (PKU) is … on the discovery, development and commercialization of clinically …
-
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
29 Mar 2024 09:01 GMT
… that these sepiapterin treatment effects are durable. … treat the broad range of PKU patients.
About Phenylketonuria
Phenylketonuria (PKU) … As with any pharmaceutical under development, there are significant … Agency
FDA: U.S. Food and Drug Administration
…
-
The top emerging pharmaceutical companies in the US
26 Mar 2024 11:25 GMT
… 60 medications and products within … clinical trial of the small molecule sepiapterin in phenylketonuria (PKU) treatment, … Ultragenyx Pharmaceutical – $434.3 m
Ultragenyx Pharmaceutical, a biopharmaceutical company dedicated to developing innovative treatments …
-
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
22 Mar 2024 07:47 GMT
… exclusive license to Eton Pharmaceuticals, Inc. (Nasdaq: … drug product candidate under development for the treatment of PKU … expected to be filed for approval before the FDA … .com .
About Phenylketonuria (PKU)
Phenylketonuria (PKU) is caused by …
-
Relief Therapeutics partners with Eton Pharma to commercialize Golike family of products in US
23 Mar 2024 06:38 GMT
… , CEO of Eton Pharmaceuticals.
Under the terms … innovative drug product candidate under development for the treatment of PKU … expected to be filed for approval before the FDA … outside the United States.
Phenylketonuria (PKU) is caused by …
-
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
22 Mar 2024 06:00 GMT
… NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or … drug product candidate under development for the treatment of PKU … .com. About Phenylketonuria (PKU) Phenylketonuria (PKU) is caused by … discovering, developing and commercializing drugs that are …